» Articles » PMID: 35699161

Potential Mechanism of SARS-CoV-2-associated Central and Peripheral Nervous System Impairment

Overview
Specialty Neurology
Date 2022 Jun 14
PMID 35699161
Authors
Affiliations
Soon will be listed here.
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is more than merely a respiratory disease, as it also presents with various neurological symptoms. SARS-CoV-2 may infect the central nervous system (CNS) and thus is neurotropic. However, the pathophysiological mechanism of coronavirus disease 2019 (COVID-19)-associated neuropathy remains unclear. Many studies have reported that SARS-CoV-2 enters the CNS through the hematogenous and neuronal routes, as well as through the main host neurological immune responses and cells involved in these responses. The neurological immune responses to COVID-19 and potential mechanisms of the extensive neuroinflammation induced by SARS-CoV-2 have been investigated. Although CNS infection with SARS-CoV-2 was shown to lead to neuronal impairment, certain aspects of this mechanism remain controversial and require further analysis. In this review, we discussed the pathway and mechanisms of SARS-CoV-2 invasion in the CNS, and associated clinical manifestations, such as anosmia, headache, and hyposmia. Moreover, the mechanism of neurological damage caused by SARS-CoV-2 may provide potential treatment methods for patients presenting with SARS-CoV-2-associated neuropathy.

Citing Articles

Neurological complications caused by SARS-CoV-2.

Pang Z, Tang A, He Y, Fan J, Yang Q, Tong Y Clin Microbiol Rev. 2024; 37(4):e0013124.

PMID: 39291997 PMC: 11629622. DOI: 10.1128/cmr.00131-24.


Neurological Impact of Respiratory Viruses: Insights into Glial Cell Responses in the Central Nervous System.

Mora V, Kalergis A, Bohmwald K Microorganisms. 2024; 12(8).

PMID: 39203555 PMC: 11356956. DOI: 10.3390/microorganisms12081713.


Clinical manifestations and EEG findings in children infected with COVID-19 and exhibiting neurological symptoms.

Yang Y, Yu T, Yang J, Luo J, Liu X, Mu C BMC Pediatr. 2024; 24(1):49.

PMID: 38229077 PMC: 10790490. DOI: 10.1186/s12887-023-04496-y.


Long-Term Effects of SARS-CoV-2 in the Brain: Clinical Consequences and Molecular Mechanisms.

Granholm A J Clin Med. 2023; 12(9).

PMID: 37176630 PMC: 10179128. DOI: 10.3390/jcm12093190.


COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters.

Rizzi M, DOnghia D, Tonello S, Minisini R, Colangelo D, Bellan M Int J Mol Sci. 2023; 24(8).

PMID: 37108262 PMC: 10138390. DOI: 10.3390/ijms24087099.


References
1.
Sa Ribero M, Jouvenet N, Dreux M, Nisole S . Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020; 16(7):e1008737. PMC: 7390284. DOI: 10.1371/journal.ppat.1008737. View

2.
Stadio A, DAscanio L, Vaira L, Cantone E, De Luca P, Cingolani C . Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial. Curr Neuropharmacol. 2022; 20(10):2001-2012. PMC: 9886808. DOI: 10.2174/1570159X20666220420113513. View

3.
Shin T, Lee D, Basith S, Manavalan B, Paik M, Rybinnik I . Metabolome Changes in Cerebral Ischemia. Cells. 2020; 9(7). PMC: 7407387. DOI: 10.3390/cells9071630. View

4.
Xu H, Akinyemi I, Chitre S, Loeb J, Lednicky J, McIntosh M . SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway. Virology. 2022; 568:13-22. PMC: 8762580. DOI: 10.1016/j.virol.2022.01.003. View

5.
Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R . Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2020; 24(2):168-175. DOI: 10.1038/s41593-020-00758-5. View